Abstract
The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Protein & Peptide Letters
Title:Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Volume: 20 Issue: 4
Author(s): Xiaoming Lu, Chao Cheng, Guobin Wang, Xiaogang Shu, Jingwei Ma and Qiang Tong
Affiliation:
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Abstract: The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.
Export Options
About this article
Cite this article as:
Lu Xiaoming, Cheng Chao, Wang Guobin, Shu Xiaogang, Ma Jingwei and Tong Qiang, Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040011
DOI https://dx.doi.org/10.2174/0929866511320040011 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Biomolecules Linked to Transition Metal Complexes - New Chances for Chemotherapy
Current Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Photodynamic Therapy in Melanoma - Where do we Stand?
Current Medicinal Chemistry Psychoimmunological Analysis of Cancer Patients: Correlation with the Prognosis
Current Aging Science Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Radiolabeled Peptides for Alzheimer’s Diagnostic Imaging: Mini Review
Current Radiopharmaceuticals Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology Epigenetic Regulation of Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Cancer-Homing Toxins
Current Pharmaceutical Design Drug Delivery Systems for Photodynamic Therapy
Recent Patents on Drug Delivery & Formulation Hedgehog Signaling and Urological Cancers
Current Drug Targets The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets